In a chronically tracheostomized patient after a cerebrovascular accident who has dysphagia, is it appropriate to schedule continuous 3% hypertonic saline nebulizations?

Scheduled Around-the-Clock 3% Hypertonic Saline Nebulizers Are Not Rationally Indicated for This Patient

There is no evidence-based rationale for scheduling continuous 3% hypertonic saline nebulizations around the clock in a chronically tracheostomized post-CVA patient with dysphagia. The available guidelines and evidence do not support this practice for dysphagia management or routine tracheostomy care in this clinical context.

Why This Practice Lacks Support

Guideline Evidence on Dysphagia Management Post-Stroke

The most recent stroke rehabilitation guidelines 1, 2, 3 consistently emphasize:

• Dysphagia screening and assessment by speech-language pathologists
• Restorative swallowing therapy (lingual resistance exercises, breath holds, effortful swallows)
• Compensatory techniques (postural adjustments, texture modifications)
• Meticulous oral hygiene to reduce pneumonia risk
• Nutritional support through appropriate feeding routes

None of these guidelines recommend hypertonic saline nebulizations as a dysphagia management strategy. 1, 2, 3

Tracheostomy Care Guidelines

The American Thoracic Society guidelines on chronic tracheostomy care 4 specifically address medication administration through tracheostomy tubes. They recommend:

• Avoiding aerosol administration of non-approved medications unless appropriate studies demonstrate safety and efficacy
• Recognizing that drugs nebulized through a tracheostomy bypass first-pass metabolism, potentially causing increased systemic absorption and toxicity
• Understanding that distribution, deposition, and local toxic effects of medications given via tracheostomy aerosol are unknown and potentially harmful

The guideline explicitly states: "Because the distribution, deposition, systemic absorption, local toxic effects, and efficacy of other (nonapproved for aerosol use) medications given via aerosol through a tracheostomy are unknown, the committee recommends avoiding such administration unless appropriate studies are performed." 4

Hypertonic Saline: Appropriate Indications

Hypertonic saline (3%) does have evidence-based uses, but not for this clinical scenario:

Appropriate use: Continuous 3% hypertonic saline infusion for elevated intracranial pressure in acute cerebrovascular disease with cerebral edema 5, 6, 7. This involves:

• Intravenous administration (not nebulized)
• Target sodium 145-155 mmol/L
• Used in acute/subacute phase with ICP monitoring
• Duration typically 7-23 days during critical illness

Your patient is chronically tracheostomized (past the acute phase) and the question concerns nebulized (not IV) administration for dysphagia management—an entirely different clinical context.

COVID-Era Tracheostomy Care Modifications

Recent multidisciplinary guidance 8 mentions that "mucolytic drugs may be a useful alternative or adjunct" and that "saline or hypertonic saline nebulisers can be of benefit" for secretion management in tracheostomized patients. However, this recommendation:

• Addresses thick secretions requiring chest clearance
• Is presented as an alternative to humidification, not routine scheduled therapy
• Notes that adding nebulizers "significantly reduces HME filter efficiency"
• Should be used judiciously based on secretion burden, not routinely scheduled

What Should Be Done Instead

For dysphagia management in this chronically tracheostomized post-CVA patient:

1. Ensure ongoing dysphagia assessment by speech-language pathologist with regular reassessment 2, 9, 10

2. Implement evidence-based swallowing interventions 2:

   • Restorative therapy (lingual resistance exercises, effortful swallows)
   • Compensatory strategies (postural modifications, texture adjustments)
   • Consider videofluoroscopy or FEES if aspiration risk unclear

3. Optimize tracheostomy management 11:

   • Maintain cuff inflation appropriately to prevent aspiration
   • Provide adequate humidification (HME or active humidification)
   • Ensure meticulous oral hygiene 1, 2, 3

4. Address secretion management only if clinically indicated 8:

   • Use mucolytics or nebulized saline as needed for thick secretions
   • Not scheduled around-the-clock without clinical indication

5. Ensure adequate nutrition through appropriate feeding route (PEG if long-term) 1, 12, 3

Common Pitfalls to Avoid

• Do not confuse IV hypertonic saline for ICP management with nebulized saline for airway care—these are completely different interventions for different indications
• Do not schedule routine nebulizers without specific indication (thick secretions, bronchospasm)—this increases care burden without evidence of benefit
• Do not substitute nebulized treatments for evidence-based dysphagia therapy 2, 9
• Remember that tracheostomy itself contributes to dysphagia through multiple mechanisms 13, 11, 14—address the underlying swallowing dysfunction, not just secretions

In summary: scheduled around-the-clock 3% hypertonic saline nebulizations lack any evidence-based rationale for this patient population and clinical scenario. Focus instead on guideline-concordant dysphagia assessment, swallowing therapy, appropriate nutrition, and tracheostomy care. 1, 2, 4, 11